Ovulation induction with rosiglitazone/clomiphene citrate versus metformin /clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome

Middle East Fertility Society Journal

Volumn 14, Issue 4, 2009, Pages 257-264

  Fayed, Mahmoud R ^a   Hamed, Thanaa ^a  

^a BENHA UNIVERSITY   (Egypt)

Author keywords

Clomiphene resistance; Metformin; Polycystic Ovary Syndrome; Rosiglitazone

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; ROSIGLITAZONE; TESTOSTERONE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FEMALE INFERTILITY; FINGER SWELLING; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; MULTIPLE CYCLE TREATMENT; NAUSEA; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SWELLING; TESTOSTERONE BLOOD LEVEL; VOMITING;

EID: 78149265292     PISSN: 11105690     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES and Yildiz BO. the prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89: 2745-2749.
2. Harshilag A, Peterson CM, Endocrine disorders. In: Rebecca DR, Paula AH, Eli YA eds. Novaks Gynecology.13th ed. Philadelphia:Lippincott Williams and Wilkins 2002;pg876-9
3. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome p450c17alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23
4. Polson DW, Kiddy DS, Mason HD and Franks S. Induction of ovulation with clomiphene citrate in women with poly cystic ovary syndrome: the difference between responders and non responders. Fertil Steril 1989; 51:30-34.
5. Metwally MF, Kuscu NK and Yalcinkaya TM. High ovulation rates, with the use of troglitazone in clomiphene-resistant women with poly cystic ovary syndrome. Hum Reprod 1999;14: 2700-2703.
6. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E and Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146.
7. Kirpichnikov D, McFarlane SI and Sowers JR. Metformin: an update.Ann Intern Med 2002;137:25-33.
8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem1995; 270: 12953-6.
9. Anonymous. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: 41-7.
10. Abraham GE, Manlimos FS, Garza R. Radioimmunoassay of steroids. In: Abraham GE ed. Handbook of Radioimmunoassay. New York: Marcel Dekker 1977: 597-620.
11. Parasanezhad ME, Bichnell J, Jones M et al., Insulin resistance in clomiphene responders and non- responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynacol Obstet 2001; 75: 43-50.
12. Haddad GF, Jodicke C, Thomas MA, Williams DB, Aubuchon M. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol. 2008;26(2):183-4.
13. Fleming R, Hopkinson Z, Wallace R. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind, placebo controlled trial. J Clin Endocrinol Metab 2002;87:569-574.
14. Dunaif A, Scott D, Finegood D, Quintana B, Whicomb R. The insulin sensitizing agent proglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J Clin Endocrinol Metab 1996;81:3299-3306.
15. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effects of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-566 (Pubitemid 36293452)
16. Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81:624-9.
17. Sepilian V and Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005;90: 60-5. (Pubitemid 40116634)
18. Ortego-Gonzalez C, Luna S, Hernandez L et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin - resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90: 1360-5.
19. Pasquali R, Casimirri F, Venturoli D, Antonio M, Morselli L, Reho S, Pezzoli A, Paradisi R. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994;6:706-13
20. Baillargeon JP, Jakubowicz DJ, Iuomo ML, Jakubowicz S and Nestler JE. Effects of metformin and rosiglitasone alone and in combination in non-obese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82:893-902.
21. Susan SG, Korula G, Christina I, victotia Job et al. Sequential treatment of metformin and clomiphene citrate in clomiphene resistant women with polycystic ovary syndrome: a randomized, controlled trial. Human Reprod. 2003; 18:299-304.
22. Vicken S. and Manubai N. Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance. 2004, Journal of Clinical Endocrinology & Metabolism. First published October 13, 2004 as doi:10.1210/jc.2004-1376.
23. Jia P, Zhao ZG, Gao HY, Zhang CL. Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. Mar 2004; 39(3):173-5.
24. Ma LK, Jin LN, Yu Q, Xu L. Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome] [Article in Chinese] Zhonghua Fu Chan Ke Za Zhi. 2007; 42(5):294-7.
25. Miyazaki Y. and De Fronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab.; 2008;10(12):1204-11.
26. Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. Diabetes Obes Metab 2008; 10(6):460-7.
27. Seto-Young D, Paliou M, Schlosser J, Avtanski D and Park A. Direct thiazolidinedione action in the human ovary; insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-l(IGFBPl) production. J Clin Endocrinol Metab 2005; 90: 6099-106.
28. Yilmaz M, Biri A, Karakoç A, Torüner F, Bingol B, Cakir N, Tiras B, Ayvaz G, Arslan M. The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2005; 28(11):1003-8. (Pubitemid 43265766)
29. Mitkov M, Pehlivanov B and Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126(1):93-8.
30. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10:99-104.
31. Giudice LC, Fechner PY, Basina M, McLaughlin, Abbasi F Cataldo NA and Reaven GM. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulinresistant women with polycystic ovary syndrome. Hum Reprod. 2006; 21(1):109-20.